H. Lee Moffitt Cancer Center and Research Institute
Who can join
18 and older, any sex, with Oropharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Response at Week 4 of TreatmentPrimary· At 4 weeks of treatment
Fractionation of radiation will be individualized based on patient Proliferation Saturation Index (PSI). Objective is to increase the rate of response of ≥ 32% at 4 weeks to 63% of patients, above the expected 49%. Result is reported as percentage of participants who met the criteria for ≥ 32% reduction in tumor volume by week 4.
Group
Value
95% CI
Radiotherapy Fractionation
61.2
Rate of Complete Response at 2-3 MonthsSecondary· 2-3 months post treatment
Rate of complete response by Computed Tomography (CT) at 2 months or Positron Emission Topography (PET)/CT at 3 months following completion of therapy
Complete anatomic and/or metabolic response
Group
Value
95% CI
Radiotherapy Fractionation
98.1
Partial anatomic and/or metabolic response
Group
Value
95% CI
Radiotherapy Fractionation
2.1
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from date participant signed informed consent to 7 days for non serious or 30 days for serious adverse events after last day of study participation, an average of 1 year..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca
· Phase 2
· recruiting
NCT06446713 — PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
· Phase 1
· recruiting
NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
· Phase 1
· recruiting
NCT05363709 — BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
· Phase 2
· active not recruiting
NCT05862792 — Liposomal Bupivacaine and Transoral Robotic Surgery
· recruiting
Other H. Lee Moffitt Cancer Center and Research Institute trials
Trials by the same sponsor.
NCT05041335 — Wet Heparinized Suction for Abdominal Cancer
· NA
· not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
· NA
· recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
· Phase 1
· recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
· Phase 2
· recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 20 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03656133.